drugset / Trial / NCT07252050
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Phase 1/2
Recruiting
24 enrolled
Arkansas Children's Hospital Research Institute
Children's Healthcare of Atlanta · collabEmory University · collabIncyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.
Timeline
- Start
- 2026-06-08
- Primary completion
- 2028-11-19
- Completion
- 2029-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | — |